A slew of pharmaceutical companies are facing a lawsuit regarding their alleged delay of the generic form of an acne medication from reaching the shelves, following a recent trend of suits involving pay-for-delay agreements.
A class action lawsuit was filed last Wednesday in federal court in Pennsylvania against makers of the drug, who are accused of harming competition through the delay of the generic form of the drug called Solodyn.
Court documents list Lupin Pharmaceuticals, Impax and other major drug companies as defendants.
The US Supreme Court ruled last June that such pay-for-delay agreements are a valid reason for filing a lawsuit, leading to a new influx of similar lawsuits.
Full Content: The Pennsylvania Record
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI